236 related articles for article (PubMed ID: 26009879)
1. Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer.
Kluth M; Runte F; Barow P; Omari J; Abdelaziz ZM; Paustian L; Steurer S; Christina Tsourlakis M; Fisch M; Graefen M; Tennstedt P; Huland H; Michl U; Minner S; Sauter G; Simon R; Adam M; Schlomm T
Int J Cancer; 2015 Nov; 137(10):2354-63. PubMed ID: 26009879
[TBL] [Abstract][Full Text] [Related]
2. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
3. Deletion of 8p is an independent prognostic parameter in prostate cancer.
Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R
Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722
[TBL] [Abstract][Full Text] [Related]
4. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
[TBL] [Abstract][Full Text] [Related]
7. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
[TBL] [Abstract][Full Text] [Related]
8. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T
Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
10. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
[TBL] [Abstract][Full Text] [Related]
11. Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.
Kluth M; Ahrary R; Hube-Magg C; Ahmed M; Volta H; Schwemin C; Steurer S; Wittmer C; Wilczak W; Burandt E; Krech T; Adam M; Michl U; Heinzer H; Salomon G; Graefen M; Koop C; Minner S; Simon R; Sauter G; Schlomm T
Oncotarget; 2015 Sep; 6(29):27966-79. PubMed ID: 26293672
[TBL] [Abstract][Full Text] [Related]
12. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
[TBL] [Abstract][Full Text] [Related]
13. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer.
Burdelski C; Reiswich V; Hube-Magg C; Kluth M; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wittmer C; Huland H; Simon R; Schlomm T; Sauter G; Steurer S
Clin Cancer Res; 2015 Aug; 21(15):3471-9. PubMed ID: 25925890
[TBL] [Abstract][Full Text] [Related]
15. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
[TBL] [Abstract][Full Text] [Related]
16. NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.
Grupp K; Ospina-Klinck D; Tsourlakis MC; Koop C; Wilczak W; Adam M; Simon R; Sauter G; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Prostate; 2014 Jul; 74(10):1012-22. PubMed ID: 24789172
[TBL] [Abstract][Full Text] [Related]
17. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C
Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607
[TBL] [Abstract][Full Text] [Related]
18. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Grupp K; Habermann M; Sirma H; Simon R; Steurer S; Hube-Magg C; Prien K; Burkhardt L; Jedrzejewska K; Salomon G; Heinzer H; Wilczak W; Kluth M; Izbicki JR; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Mod Pathol; 2014 Jan; 27(1):96-106. PubMed ID: 23887301
[TBL] [Abstract][Full Text] [Related]
19. Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers.
Müller J; Ehlers A; Burkhardt L; Sirma H; Steuber T; Graefen M; Sauter G; Minner S; Simon R; Schlomm T; Michl U
Int J Cancer; 2013 Mar; 132(6):1333-40. PubMed ID: 22886792
[TBL] [Abstract][Full Text] [Related]
20. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence.
Grupp K; Kohl S; Sirma H; Simon R; Steurer S; Becker A; Adam M; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Mod Pathol; 2013 May; 26(5):733-42. PubMed ID: 23196798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]